6/29/23, 1:34 AM PACMAN-AMI Pathway Feedback Search Clinical Topics Home Studies PACMAN AMI PACMAN AMI Disease Disease Non-ST-elevation myocardial inf ST-elevation myocardial infarction Trial question What is the effect of adding alirocumab to high-intensity statin therapy in patients with acute myocardial infarction? Study design Multi-center Double blinded RCT Population Characteristics of study participants 19.0% female N = 300 81.0% male 300 patients (56 female, 243 male) Inclusion criteria: adult patients undergoing PCI for acute myocardial infarction Key exclusion criteria: left main or 3-vessel coronary artery disease; history of coronary artery bypass surgery; severe kidney dysfunction, liver disease, or known statin intolerance Interventions N=148 alirocumab (subcutaneous dose of 150 mg biweekly) N=152 placebo (subcutaneous administration of matching placebo biweekly) Primary outcome Reduction in atheroma volume at week 52 https://web.pathway.md/studies/recz0SeZ02JC3Jbz9 1/2 6/29/23, 1:34 AM PACMAN-AMI Pathway 2.1 % 2.13 1.6 % 1.1 % 0.92 Significant increase 0.5 % NNT = 83 0.0 % Alirocumab Placebo Significant increase in reduction in atheroma volume at week 52 (2.13% vs. 0.92%; AD 1.21%, 95% CI 0.65 to 1.78) Secondary outcomes Significant increase in reduction in maximum lipid core burden index within 4 mm (79.42 vs. 37.6; AD 41.24, 95% CI 11.77 to 70.71) Significant increase in improvement in minimal fibrous cap thickness (62.67 um vs. 33.19 um; AD 29.65 um, 95% CI 11.75 to 47.55) Safety outcomes No significant difference in adverse events. Conclusion In adult patients undergoing PCI for acute myocardial infarction, alirocumab was superior to placebo with respect to reduction in atheroma volume at week 52. Reference Lorenz R ber, MD, PhD et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction The PACMAN-AMI Randomized Clinical Trial. JAMA. 2022 May 10;327(18):1771-1781. Open reference URL https://web.pathway.md/studies/recz0SeZ02JC3Jbz9 2/2